ANTIVERT
Pronunciation: MEK-li-zeen


What it isCentrally acting H1 antihistamine; vertigo and motion sickness.
Why this oneWorks on vestibular nausea, where ondansetron does not.
What limits itSedation and fall risk, so poor in the elderly. It suppresses vestibular compensation, so it should not be continued for weeks.
Animated chart of estimated U.S. prescriptions per year, Antiemetics (1946–2026). Meclizine enters in 1953 (estimated).
Principal riskSedation and fall risk
Legacy pregnancy categoryC
Defining liabilitySedation, QT prolongation, extrapyramidal symptoms or anticholinergic toxicity vary by receptor target.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Vertigo associated with diseases affecting the vestibular system | Adults | 25–100 mg/day in divided doses | 25–100 mg/day in divided doses, per clinical response | 100 mg/day |
Renal Use with caution (potential drug/metabolite accumulation); also in the elderly
Hepatic Use with caution (increased systemic exposure possible)
Safety and effectiveness in pediatric patients not established
Available strengths
Pregnancy Epidemiological studies have not generally indicated a risk of major birth defects; fetal malformations in rats at doses similar to clinical
Lactation No data on presence in human milk, effects on the breastfed infant, or milk production
Generic entry1982
Open Meclizine in the interactive console ↗

Open Meclizine in the interactive console ↗